Make your money go further for just 25p per day

PREMIUM

Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · AstraZeneca (AZN)  · Compass (CPG)  · Diageo (DGE)  · GSK (GSK)  · Next (NXT)  · Persimmon (PSN)  · Relx (RELX)  · Unilever (ULVR) 

Dividends FTSE 100 Investment Ideas UK

Relx logo on board in headquarters

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies which might follow Vodafone’s lead and cut their pay-outs. But the stocks whose dividends you can rely on come with an added valuation risk which investors might want to avoid.


In part one of our mini-series on dividends, we looked at the FTSE 100 companies which are likely to follow Vodafone’s lead and cut their dividends in 2019. We suggested that a yield of over 8% is a major red flag for investors considering the future of their income.

But if you’re going to dump the dividend dogs out of fear of a cut, where should you re-invest your money if you want to continue to…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on AstraZeneca

Overhyped perhaps - but don’t ignore AI!

03/07/2024 · Company Insights

Is AI overhyped? Of course it is, but there are still plenty of opportunities for investors…


AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · Company Insights

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes…


More on Compass

Dividend dogs vs diamonds: Part 2 – paying the price of quality

23/05/2019 · Company Insights

With seven FTSE 100 dividend stalwarts currently yielding over 8%, investors are starting to ditch companies…


More on Diageo

Episode 29 of the Investor’s Champion Podcast

04/08/2024 · Podcasts

In this episode of the Investors Champion Podcast, hosts Chris and Lee discuss a variety of…


Game delights | Consumer facing weakness | Tech delivers

02/08/2024 · Portfolio

Most of our Ultimate Stocks continue to deliver excellent results although it’s more of a struggle…


More on GSK

Overhyped perhaps - but don’t ignore AI!

03/07/2024 · Company Insights

Is AI overhyped? Of course it is, but there are still plenty of opportunities for investors…


Mega-Trends Portfolio: CRISPR is the future

17/03/2021 · Portfolio

We have covered CRISPR/Cas9 before and hailed it as one of the most important inventions of…


More on Next

Episode 34 of the Investor’s Champion Podcast

21/09/2024 · Podcasts

In this episode of the Investors Champion Podcast, Chris and Lee discuss Next PLC's latest interim…


Episode 10 of the Investor’s Champion Podcast

23/03/2024 · Podcasts

This episode of the Investor's Champion Podcast discusses the value (or not) in automakers, Apple's lawsuits, Unilever's latest…


More on Persimmon

Do our Income Boosters need a housebuilder?

29/03/2021 · Portfolio

With UK housebuilders offering yields up to 8%, should we add one to our Income Boosters dividend…


Income Boosters: Does our dividend portfolio need a housebuilder?

18/09/2020 · Portfolio

Housebuilders have become income favourites in recent years, but our income portfolio doesn't have any exposure…


More on Relx

Ultimate Stocks company updates: luxurious returns

20/10/2023 · Portfolio

Our Ultimate Stocks portfolio of high-quality companies continue to deliver impressive updates, as you can discover…


Ultimate Stocks: Recovery gathering momentum in 2023

13/02/2023 · Portfolio

In 2022 the Ultimate Stocks Portfolio lost 16% - ahead of its benchmark and many quality…


More on Unilever

Episode 28 of the Investor’s Champion Podcast

27/07/2024 · Podcasts

This episode of the Investors Champion Podcast, touches on the tech sector's recent sell-off, the investment…


Income Boosters: making progress in mixed markets

26/07/2024 · Portfolio

July was a busy month for our high yield Income Boosters portfolio, with five companies reporting during…


More Company Insights

Elderly challenges | Demotion | Australian boost

21/11/2024 · Churchill China · CVS Group · Renold · Tracsis

Bonkers Bargains: poised to recover with a new CEO

20/11/2024 · James Cropper

Improving returns | Questionable business models

More on AstraZeneca

Overhyped perhaps - but don’t ignore AI!

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

Coronavirus impact: 29 April - surging profits and depression era declines

Global investment round-up: this week’s top stories

More on Compass

Dividend dogs vs diamonds: Part 2 – paying the price of quality

More on Diageo

Episode 29 of the Investor’s Champion Podcast

Game delights | Consumer facing weakness | Tech delivers

Ultimate Stocks Portfolio: company updates

Episode 2 of the Investor’s Champion Podcast

More on GSK

Overhyped perhaps - but don’t ignore AI!

Mega-Trends Portfolio: CRISPR is the future

CRISPR: one of the most important inventions of the century?

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

More on Next

Episode 34 of the Investor’s Champion Podcast

Episode 10 of the Investor’s Champion Podcast

Are Next and Burberry ready for the new retail normal?

Coronavirus impact: 29 July - a lesson in excellent financial reporting

More on Persimmon

Do our Income Boosters need a housebuilder?

Income Boosters: Does our dividend portfolio need a housebuilder?

Coronavirus impact: 29 April - surging profits and depression era declines

European expansion boosts IHT qualifying Michelmersh

More on Relx

Ultimate Stocks company updates: luxurious returns

Ultimate Stocks: Recovery gathering momentum in 2023

Ultimate Stocks portfolio: company updates

Class is permanent!

More on Unilever

Episode 28 of the Investor’s Champion Podcast

Income Boosters: making progress in mixed markets

Ultimate Stocks portfolio: company news

Income Boosters: April ‘24 portfolio update

More Company Insights

Elderly challenges | Demotion | Australian boost
Bonkers Bargains: poised to recover with a new CEO
Improving returns | Questionable business models

Sign-up to our free email updates

SIGN UP